+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Vascular Malformations Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2025-2034)

  • PDF Icon

    Report

  • 400 Pages
  • June 2025
  • Region: Global
  • Expert Market Research
  • ID: 6100939
The vascular malformations market was valued at USD 2.98 Billion in 2024, driven by the growing advancements in imaging technologies across the 8 major markets. The market is anticipated to grow at a CAGR of 6.50% during the forecast period of 2025-2034, with the values likely to reach USD 5.59 Billion by 2034.

Vascular Malformations Market Overview

Vascular malformations are abnormal growths of blood vessels that can occur in various parts of the body, leading to the formation of a network of dilated vessels. These malformations can be present at birth or develop later in life and may cause symptoms like swelling, pain, and bleeding. Treatment options include surgery, sclerotherapy, and laser therapy, depending on the type and location.

Vascular Malformations Market Growth Drivers

Genetic Disorder Research Expands Treatment Options for Vascular Malformations

The increasing focus on precision medicine and the rise in genetic disorder research are key drivers of growth in the vascular malformations market. Advances in genetic research and treatment development for rare conditions, such as vascular malformations, have accelerated over recent years, bringing new treatment options to the forefront. For instance, in July 2024, a study demonstrated the potential of the anticancer drug sotorasib for treating arteriovenous malformations (AVMs) caused by mutations in the KRAS gene. Sotorasib, used for treating non-small cell lung cancer, showed promising effects in preclinical models, preventing the development of vascular malformations. This breakthrough suggests that sotorasib could provide a novel therapeutic avenue for patients with severe AVMs, potentially driving market growth for treatments targeting genetic vascular malformations during the forecast period.

Surge in Advanced Research and Development Initiatives to Boost Vascular Malformations Market Demand

The growing adoption of innovative experimental models and genetic research into vascular disorders is expected to drive significant development in the vascular malformations market. The creation of models that mimic specific vascular malformations enables more accurate preclinical testing and targeted therapies. For instance, in February 2023, a research team from the University of North Carolina developed a microfluidic model that mimics a rare genetic disorder affecting blood and lymphatic vessels. The model focuses on PIK3CA-activating mutations, a gene responsible for various vascular malformations. By providing a more precise model for understanding these rare disorders, the research could pave the way for new treatments targeting PIK3CA-related vascular malformations. This advancement is expected to further stimulate market development, driving demand for more targeted therapies and innovations in the coming years.

Vascular Malformations Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Increased Focus on Non-Invasive Treatment Modalities

Non-invasive treatments, such as laser therapy and sclerotherapy, are gaining traction in the vascular malformations market due to their reduced recovery times and fewer complications compared to traditional surgical approaches. This shift towards minimally invasive procedures is expected to drive market growth as patients seek effective, less invasive solutions for managing vascular malformations.

Advancements in Imaging Technologies to Boost Vascular Malformations Market Value

The adoption of advanced imaging technologies, including MRI and ultrasound, is improving the diagnosis and treatment of vascular malformations. These technologies enable more precise identification of lesion locations and sizes, allowing for personalised treatment plans. The increasing availability and accuracy of diagnostic tools are expected to boost the market by enhancing clinical outcomes and treatment efficacy.

Rising Awareness and Early Diagnosis to Meet Increasing Vascular Malformations Market Demand

As awareness of vascular malformations increases, earlier diagnosis and treatment become more common. Greater public and healthcare provider awareness of symptoms, such as visible birthmarks or swelling, is leading to earlier interventions. This trend is anticipated to drive market growth by reducing complications and improving long-term outcomes for patients.

Growing Demand for Targeted Therapies in Vascular Malformation Treatment

There is a growing demand for targeted therapies and biologics in the treatment of vascular malformations. These therapies offer higher precision and better patient outcomes compared to traditional treatments, contributing to an expanding market. The focus on innovative treatments, such as gene therapy and targeted anti-VEGF drugs, is likely to dominate the market development in the coming years.

Vascular Malformations Market Segmentation

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Type

  • Capillary Vascular Malformations
  • Venous Malformations
  • Spider Angiomas
  • Pyogenic Granulomas
  • Angiofibromas
  • Hemangioma
  • Others

Market Breakup by Drugs

  • Sirolimus
  • Sodium Tetradecyl Sulfate
  • Ethanol
  • Others

Market Breakup by End User

  • Hospital
  • Homecare
  • Specialty Clinics
  • Others

Market Breakup by Region

  • United States
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Japan
  • India

Vascular Malformations Market Share

Market Segmentation Based on Drugs to Witness Significant Growth

The Sirolimus segment is estimated to lead the market share by drugs, due to its proven efficacy in treating complex vascular lesions. Sirolimus, an immunosuppressive drug, helps reduce the size of these malformations and is widely used for conditions like lymphatic malformations. Its ability to effectively manage symptoms and prevent further complications positions it as the most popular choice. The segment’s dominance is further supported by ongoing clinical studies and a growing understanding of its mechanism of action in treating vascular malformations.

Vascular Malformations Market Analysis by Region

The United States dominates the market due to its advanced healthcare infrastructure, high treatment demand, and the presence of key players in the medical device and pharmaceutical sectors. Additionally, the strong adoption of innovative therapies, high healthcare spending, and well-established reimbursement policies contribute to its market leadership. The increasing prevalence of vascular malformations and the availability of advanced diagnostic and therapeutic options further fuel the market's growth in the US during the forecast period.

Leading Players in the Vascular Malformations Market

The key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Galderma Pharma S.A.

Headquartered in Lausanne, Switzerland, Galderma Pharma S.A. was established in 1981. Galderma's portfolio specialises in dermatology and includes injectables and devices for reducing wrinkles and other skin concerns.

Novartis AG

Founded in 1996 and headquartered in Basel, Switzerland, Novartis AG is a global healthcare company. It offers a broad portfolio of innovative medicines, including treatments for oncology, immunology, ophthalmology, and neuroscience. Novartis is also active in the cardiovascular, dermatology, and respiratory markets, providing a comprehensive range of healthcare solutions.

Bayer AG

Bayer AG, established in 1863 and based in Leverkusen, Germany, is a leading global pharmaceutical and life sciences company. Its diverse portfolio includes medications for oncology, cardiology, and women's health, along with dermatology and ophthalmology treatments. Bayer also provides agricultural solutions, veterinary products, and consumer health goods.

Cook Medical LLC

Cook Medical LLC, established in 1963 and headquartered in Bloomington, Indiana, USA, is a prominent medical device manufacturer. The company offers a wide range of products for interventional radiology, urology, cardiology, and vascular care. Cook Medical focuses on innovative solutions for minimally invasive procedures across several medical specialities.

Other key players in the market include Sirtex Medical Limited.

Key Questions Answered in the Vascular Malformations Market

  • What was the vascular malformations market value in 2024?
  • What is the vascular malformations market forecast outlook for 2025-2034?
  • What is the market breakup based on the type?
  • What is the market breakup based on the drugs?
  • What is the market breakup based on the end user?
  • How has the market performed so far and how is it anticipated to perform in the coming years?
  • What are the market's major drivers, opportunities, and restraints?
  • Which country is expected to experience expedited growth during the forecast period?
  • What are the major vascular malformations market trends?
  • Which type will lead the market segment?
  • Which drugs will lead the market segment?
  • Which end user will lead the market segment?
  • Who are the key players involved in the venous ulcer market?
  • What is the patent landscape of the market?
  • What are the current unmet needs and challenges in the market?
  • How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Vascular Malformations Market Overview - 8 Major Markets
3.1 Vascular Malformations Market Historical Value (2018-2024)
3.2 Vascular Malformations Market Forecast Value (2025-2034)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Vascular Malformations Overview
5.1 Guidelines and Stages
5.2 Pathophysiology
5.3 Screening and Diagnosis
5.4 Treatment Pathway
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
6.3 Risk Assessment and Treatment Success Rate
7 Vascular Malformations Market - Epidemiology Scenario and Forecast - 8 Major Markets
7.1 8MM Epidemiology Scenario Overview (2018-2034)
7.2 Prevalence, by Country
7.2.1 United States
7.2.2 United Kingdom
7.2.3 Germany
7.2.4 France
7.2.5 Italy
7.2.6 Spain
7.2.7 India
7.2.8 Japan
7.3 Diagnosed Cases, by Country
7.3.1 United States
7.3.2 United Kingdom
7.3.3 Germany
7.3.4 France
7.3.5 Italy
7.3.6 Spain
7.3.7 India
7.3.8 Japan
7.4 Treatment Seeking Rate, by Country
7.4.1 United States
7.4.2 United Kingdom
7.4.3 Germany
7.4.4 France
7.4.5 Italy
7.4.6 Spain
7.4.7 India
7.4.8 Japan
8 Vascular Malformations Market Landscape - 8 Major Markets
8.1 Vascular Malformations Market: Developers Landscape
8.1.1 Analysis by Year of Establishment
8.1.2 Analysis by Company Size
8.1.3 Analysis by Region
8.2 Vascular Malformations Market: Product Landscape
8.2.1 Analysis by Treatment
8.2.2 Analysis by Route of Administration
9 Vascular Malformations Market Challenges and Unmet Needs
9.1 Treatment Pathway Challenges
9.2 Compliance and Drop-Out Analysis
9.3 Awareness and Prevention Gaps
10 Cost of Treatment
11 Vascular Malformations Market Dynamics
11.1 Market Drivers and Constraints
11.2 SWOT Analysis
11.2.1 Strengths
11.2.2 Weaknesses
11.2.3 Opportunities
11.2.4 Threats
11.3 PESTEL Analysis
11.3.1 Political
11.3.2 Economic
11.3.3 Social
11.3.4 Technological
11.3.5 Legal
11.3.6 Environment
11.4 Porter’s Five Forces Model
11.4.1 Bargaining Power of Suppliers
11.4.2 Bargaining Power of Buyers
11.4.3 Threat of New Entrants
11.4.4 Threat of Substitutes
11.4.5 Degree of Rivalry
11.5 Key Demand Indicators
11.6 Key Price Indicators
11.7 Industry Events, Initiatives, and Trends
11.8 Value Chain Analysis
12 Vascular Malformations Market Segmentation (218-2034) - 8 Major Markets
12.1 Vascular Malformations Market (2018-2034) by Type
12.1.1 Market Overview
12.1.2 Capillary Vascular Malformations
12.1.3 Venous Malformations
12.1.4 Spider Angiomas
12.1.5 Pyogenic Granulomas
12.1.6 Angiofibromas
12.1.7 Hemangioma
12.1.8 Others
12.2 Vascular Malformations Market (2018-2034) by Drugs
12.2.1 Market Overview
12.2.2 Sirolimus
12.2.3 Sodium Tetradecyl Sulfate
12.2.4 Ethanol
12.2.5 Others
12.3 Vascular Malformations Market (2018-2034) by End User
12.3.1 Market Overview
12.3.2 Hospital
12.3.3 Homecare
12.3.4 Specialty Clinics
12.3.5 Others
12.4 Vascular Malformations Market (2018-2034) by Region
12.4.1 Market Overview
12.4.2 United States
12.4.3 United Kingdom
12.4.4 Germany
12.4.5 France
12.4.6 Italy
12.4.7 Spain
12.4.8 Japan
12.4.9 India
13 United States Vascular Malformations Market (218-2034)
13.1 United States Vascular Malformations Market Historical Value (2018-2024)
13.2 United States Vascular Malformations Market Forecast Value (2025-2034)
13.3 United States Vascular Malformations Market (2018-2034) by Type
13.3.1 Market Overview
13.3.2 Capillary Vascular Malformations
13.3.3 Venous Malformations
13.3.4 Spider Angiomas
13.3.5 Pyogenic Granulomas
13.3.6 Angiofibromas
13.3.7 Hemangioma
13.3.8 Others
13.4 United States Vascular Malformations Market (2018-2034) by Drugs
13.4.1 Market Overview
13.4.2 Sirolimus
13.4.3 Sodium Tetradecyl Sulfate
13.4.4 Ethanol
13.4.5 Others
13.5 United States Vascular Malformations Market (2018-2034) by End User
13.5.1 Market Overview
13.5.2 Hospital
13.5.3 Homecare
13.5.4 Specialty Clinics
13.5.5 Others
14 United Kingdom Vascular Malformations Market (218-2034)
14.1 United Kingdom Vascular Malformations Market Historical Value (2018-2024)
14.2 United Kingdom Vascular Malformations Market Forecast Value (2025-2034)
14.3 United Kingdom Vascular Malformations Market (2018-2034) by Type
14.3.1 Market Overview
14.3.2 Capillary Vascular Malformations
14.3.3 Venous Malformations
14.3.4 Spider Angiomas
14.3.5 Pyogenic Granulomas
14.3.6 Angiofibromas
14.3.7 Hemangioma
14.3.8 Others
14.4 United Kingdom Vascular Malformations Market (2018-2034) by Drugs
14.4.1 Market Overview
14.4.2 Sirolimus
14.4.3 Sodium Tetradecyl Sulfate
14.4.4 Ethanol
14.4.5 Others
14.5 United Kingdom Vascular Malformations Market (2018-2034) by End User
14.5.1 Market Overview
14.5.2 Hospital
14.5.3 Homecare
14.5.4 Specialty Clinics
14.5.5 Others
15 Germany Vascular Malformations Market (218-2034)
15.1 Germany Vascular Malformations Market Historical Value (2018-2024)
15.2 Germany Vascular Malformations Market Forecast Value (2025-2034)
15.3 Germany Vascular Malformations Market (2018-2034) by Type
15.3.1 Market Overview
15.3.2 Capillary Vascular Malformations
15.3.3 Venous Malformations
15.3.4 Spider Angiomas
15.3.5 Pyogenic Granulomas
15.3.6 Angiofibromas
15.3.7 Hemangioma
15.3.8 Others
15.4 Germany Vascular Malformations Market (2018-2034) by Drugs
15.4.1 Market Overview
15.4.2 Sirolimus
15.4.3 Sodium Tetradecyl Sulfate
15.4.4 Ethanol
15.4.5 Others
15.5 Germany Vascular Malformations Market (2018-2034) by End User
15.5.1 Market Overview
15.5.2 Hospital
15.5.3 Homecare
15.5.4 Specialty Clinics
15.5.5 Others
16 France Vascular Malformations Market (218-2034)
16.1 France Vascular Malformations Market Historical Value (2018-2024)
16.2 France Vascular Malformations Market Forecast Value (2025-2034)
16.3 France Vascular Malformations Market (2018-2034) by Type
16.3.1 Market Overview
16.3.2 Capillary Vascular Malformations
16.3.3 Venous Malformations
16.3.4 Spider Angiomas
16.3.5 Pyogenic Granulomas
16.3.6 Angiofibromas
16.3.7 Hemangioma
16.3.8 Others
16.4 France Vascular Malformations Market (2018-2034) by Drugs
16.4.1 Market Overview
16.4.2 Sirolimus
16.4.3 Sodium Tetradecyl Sulfate
16.4.4 Ethanol
16.4.5 Others
16.5 France Vascular Malformations Market (2018-2034) by End User
16.5.1 Market Overview
16.5.2 Hospital
16.5.3 Homecare
16.5.4 Specialty Clinics
16.5.5 Others
17 Italy Vascular Malformations Market (218-2034)
17.1 Italy Vascular Malformations Market Historical Value (2018-2024)
17.2 Italy Vascular Malformations Market Forecast Value (2025-2034)
17.3 Italy Vascular Malformations Market (2018-2034) by Type
17.3.1 Market Overview
17.3.2 Capillary Vascular Malformations
17.3.3 Venous Malformations
17.3.4 Spider Angiomas
17.3.5 Pyogenic Granulomas
17.3.6 Angiofibromas
17.3.7 Hemangioma
17.3.8 Others
17.4 Italy Vascular Malformations Market (2018-2034) by Drugs
17.4.1 Market Overview
17.4.2 Sirolimus
17.4.3 Sodium Tetradecyl Sulfate
17.4.4 Ethanol
17.4.5 Others
17.5 Italy Vascular Malformations Market (2018-2034) by End User
17.5.1 Market Overview
17.5.2 Hospital
17.5.3 Homecare
17.5.4 Specialty Clinics
17.5.5 Others
18 Spain Vascular Malformations Market (218-2034)
18.1 Spain Vascular Malformations Market Historical Value (2018-2024)
18.2 Spain Vascular Malformations Market Forecast Value (2025-2034)
18.3 Spain Vascular Malformations Market (2018-2034) by Type
18.3.1 Market Overview
18.3.2 Capillary Vascular Malformations
18.3.3 Venous Malformations
18.3.4 Spider Angiomas
18.3.5 Pyogenic Granulomas
18.3.6 Angiofibromas
18.3.7 Hemangioma
18.3.8 Others
18.4 Spain Vascular Malformations Market (2018-2034) by Drugs
18.4.1 Market Overview
18.4.2 Sirolimus
18.4.3 Sodium Tetradecyl Sulfate
18.4.4 Ethanol
18.4.5 Others
18.5 Spain Vascular Malformations Market (2018-2034) by End User
18.5.1 Market Overview
18.5.2 Hospital
18.5.3 Homecare
18.5.4 Specialty Clinics
18.5.5 Others
19 Japan Vascular Malformations Market
19.1 Japan Vascular Malformations Market Historical Value (2018-2024)
19.2 Japan Vascular Malformations Market Forecast Value (2025-2034)
19.3 Japan Vascular Malformations Market (2018-2034) by Type
19.3.1 Market Overview
19.3.2 Capillary Vascular Malformations
19.3.3 Venous Malformations
19.3.4 Spider Angiomas
19.3.5 Pyogenic Granulomas
19.3.6 Angiofibromas
19.3.7 Hemangioma
19.3.8 Others
19.4 Japan Vascular Malformations Market (2018-2034) by Drugs
19.4.1 Market Overview
19.4.2 Sirolimus
19.4.3 Sodium Tetradecyl Sulfate
19.4.4 Ethanol
19.4.5 Others
19.5 Japan Vascular Malformations Market (2018-2034) by End User
19.5.1 Hospitals
19.5.2 Hospital
19.5.3 Homecare
19.5.4 Specialty Clinics
19.5.5 Others
20 India Vascular Malformations Market
20.1 India Vascular Malformations Market Historical Value (2018-2024)
20.2 India Vascular Malformations Market Forecast Value (2025-2034)
20.3 India Vascular Malformations Market (2018-2034) by Type
20.3.1 Market Overview
20.3.2 Capillary Vascular Malformations
20.3.3 Venous Malformations
20.3.4 Spider Angiomas
20.3.5 Pyogenic Granulomas
20.3.6 Angiofibromas
20.3.7 Hemangioma
20.3.8 Others
20.4 India Vascular Malformations Market (2018-2034) by Drugs
20.4.1 Market Overview
20.4.2 Sirolimus
20.4.3 Sodium Tetradecyl Sulfate
20.4.4 Ethanol
20.4.5 Others
20.5 India Vascular Malformations Market (2018-2034) by End User
20.5.1 Market Overview
20.5.2 Hospital
20.5.3 Homecare
20.5.4 Specialty Clinics
20.5.5 Others
21 Regulatory Framework
21.1 Regulatory Overview
21.2 US FDA
21.3 EU EMA
21.4 Japan PMDA
21.5 India CDSCO
21.6 Others
22 Patent Analysis
22.1 Analysis by Type of Patent
22.2 Analysis by Publication Year
22.3 Analysis by Issuing Authority
22.4 Analysis by Patent Age
22.5 Analysis by CPC Analysis
22.6 Analysis by Patent Valuation
23 Clinical Trials Analysis
23.1 Analysis by Trial Registration Year
23.2 Analysis by Trial Status
23.3 Analysis by Trial Phase
23.4 Analysis by Therapeutic Area
23.5 Analysis by Geography
24 Grants Analysis
24.1 Analysis by Year
24.2 Analysis by Amount Awarded
24.3 Analysis by Issuing Authority
24.4 Analysis by Grant Application
24.5 Analysis by Funding Institute
24.6 Analysis by NIH Departments
24.7 Analysis by Recipient Organization
25 Funding and Investment Analysis
25.1 Analysis by Funding Instances
25.2 Analysis by Drug Class of Funding
25.3 Analysis by Funding Amount
25.4 Analysis by Leading Players
25.5 Analysis by Leading Investors
25.6 Analysis by Geography
26 Strategic Initiatives
26.1 Analysis by Partnership Instances
26.2 Analysis by Drug Class of Partnership
26.3 Analysis by Leading Players
26.4 Analysis by Geography
27 Supplier Landscape
27.1 Market Share Analysis, By Region (Top 5 Companies)
27.2 Galderma Pharma S.A.
27.2.1 Financial Analysis
27.2.2 Product Portfolio
27.2.3 Demographic Reach and Achievements
27.2.4 Company News and Developments
27.2.5 Certifications
27.3 Novartis AG
27.3.1 Financial Analysis
27.3.2 Product Portfolio
27.3.3 Demographic Reach and Achievements
27.3.4 Company News and Developments
27.3.5 Certifications
27.4 Bayer AG
27.4.1 Financial Analysis
27.4.2 Product Portfolio
27.4.3 Demographic Reach and Achievements
27.4.4 Company News and Developments
27.4.5 Certifications
27.5 Cook Medical LLC
27.5.1 Financial Analysis
27.5.2 Product Portfolio
27.5.3 Demographic Reach and Achievements
27.5.4 Company News and Developments
27.5.5 Certifications
27.6 Sirtex Medical Limited
27.6.1 Financial Analysis
27.6.2 Product Portfolio
27.6.3 Demographic Reach and Achievements
27.6.4 Company News and Developments
27.6.5 Certifications
28 Vascular Malformations Market - Distribution Model (Additional Insight)
28.1 Overview
28.2 Potential Distributors
28.3 Key Parameters for Distribution Partner Assessment
29 Key Opinion Leaders (KOL) Insights (Additional Insight)
30 Payment Methods (Additional Insight)
30.1 Government Funded
30.2 Private Insurance
30.3 Out-of-Pocket

Companies Mentioned

  • Galderma Pharma S.A.
  • Novartis AG
  • Bayer AG
  • Cook Medical LLC

Table Information